Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
Appointed director
BIOCEPT INC (BIOC) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/22/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Biocept Reports Second Quarter 2023 Financial Results SAN DIEGO—--Aug. 14, 2023— Biocept, Inc. , a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and six months ended June 30, 2023 and provides a business update. “Biocept's primary focus is establishing our proprietary cerebrospinal fluid assay CNSide ™ as standard of care. We continue to diligently work towards submission to the National Comprehensive Cancer Network ® for consideration to include CNSide in their standard-of-care guidelines. We believe securing this status will broaden physician adoption and support reimbursement that reflects our test's value in clinical decision-making,” said Antonino Morales, Biocept President and CEO. “Our ongoing FORESEE clinical trial i..."
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
06/02/2023 SC 13G Lind Global Fund II LP reports a 9.9% stake in Biocept, Inc.
05/25/2023 424B4 Form 424B4 - Prospectus [Rule 424(b)(4)]:
05/25/2023 EFFECT Form EFFECT - Notice of Effectiveness:
05/23/2023 S-1/A Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
05/19/2023 S-1/A Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
05/16/2023 S-1/A Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
05/16/2023 8-K Material Modifications to Rights of Security Holders, Financial Statements and Exhibits  Interactive Data
Docs: "Certificate of Amendment to Amended and Restated Certificate of Incorporation of Biocept, Inc",
"Certificate of Amendment to Amended and Restated Certificate of Incorporation of Biocept, Inc"
05/15/2023 S-1/A Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
05/15/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Biocept Reports First Quarter 2023 Financial Results SAN DIEGO - Biocept, Inc. , a leading provider of molecular diagnostic assays, products and services, reports financial results for the three months ended March 31, 2023 and provides a business update. “I'm exceptionally pleased with the progress being made with our FORESEE clinical trial, which is specifically designed to generate evidence of CNSide ™ 's clinical utility to support adoption into clinical care guidelines and further broaden physician use. Trial enrollment is running well in line with our plan, and we've now activated clinical sites in Dallas, Los Angeles and the San Francisco Bay Area,” said Samuel D. Riccitelli, Biocept's Chairman, and interim President and CEO. “In our quest to gain further physician and payor acceptan..."
05/10/2023 10-Q Quarterly Report for the period ended March 31, 2023
04/21/2023 DEFR14A Form DEFR14A - Revised definitive proxy soliciting materials:
04/20/2023 S-1 Form S-1 - General form for registration of securities under the Securities Act of 1933:
04/20/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/17/2023 10-K Annual Report for the period ended December 31, 2022
04/17/2023 8-K Quarterly results
04/17/2023 10-Q/A Quarterly Report for the period ended September 30, 2022 [amend]
04/17/2023 8-K Quarterly results
03/20/2023 8-K Quarterly results
01/06/2023 8-K Results of Operations and Financial Condition, Cost Associated with Exit or Disposal Activities, Other Events, Financial Stat...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Biocept to Explore Strategic Alternatives and Implement Restructuring Plan SAN DIEGO - Biocept, Inc. today announced that it has commenced a process to explore and evaluate strategic alternatives to enhance shareholder value. Biocept has engaged EF Hutton, division of Benchmark Investments, Inc., as its financial advisor to assist in this process. Potential strategic alternatives that may be explored or evaluated as part of this process include an acquisition, merger, reverse merger, other business combination, sales of assets, licensing or other strategic transactions involving the company. There can be no assurance of a successful outcome from these efforts, or of the form or timing of any such outcome. The company does not intend to make any further disclosures regarding the strategic r..."
11/21/2022 8-K Quarterly results
11/21/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/18/2022 8-K Quarterly results
11/14/2022 NT 10-Q Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB:
11/14/2022 8-K Quarterly results
11/10/2022 10-Q Quarterly Report for the period ended June 30, 2022
10/19/2022 8-K Quarterly results
08/22/2022 8-K Quarterly results
08/16/2022 NT 10-Q Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB:
07/14/2022 8-K Quarterly results
07/13/2022 8-K Quarterly results
06/27/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
06/27/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy